According to Dr Daniel Weber, the gut is the second organ system in evolution and is by far, the most complex.
SIBO causes inflammation both in the gut and systemically and is notoriously difficult to treat, with high relapse rates, so finding new treatment protocols for SIBO is hugely beneficial.
Recent research explored whether there is a relationship between proton pump inhibitor (PPI) use in irritable bowel syndrome (IBS) and small intestinal bacterial overgrowth (SIBO).
It is estimated that the global prevalence of IBS is 11%. The most common cause of IBS is small intestinal bacterial overgrowth (SIBO) — in fact, a whopping 60-80% of IBS is due to this common condition, totalling a possible 500 million people worldwide.
Abdominal pain is one of the most common diagnoses in hospitalised children and the leading symptom in child and adolescent GIT diseases. It is also a common symptom of SIBO.
In this clinically-focussed workshop, gastrointestinal expert Alessandra Edwards will share with you the latest research and therapeutic approach to diagnose and treat small intestinal bacterial overgrowth (SIBO) and parasites such as Blastocystis hominis and Dientamoeba fragilis.
Dr Steven Sandberg-Lewis is a leading pioneer in the field of SIBO and other functional gastrointestinal disorders. Today he shares his insights on the IBS - SIBO connection.
Bloating, foul-smelling wind, chronic abdominal discomfort, nausea, even malnutrition. These are all symptoms of SIBO - Small Intestinal Bacterial Overgrowth.